Patients with acute myeloid leukemia that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment.
The COVID-19 vaccine rollout is underway, bringing a sense of hope — as well as many questions about safety and who should get the vaccine. To help answer these questions, NewYork-Presbyterian experts address common concerns about the new Moderna and Pfizer-BioNTech COVID-19 vaccines and explain why they are safe.
Doctors may be able to predict their patients’ risks of fatal coronary heart disease more accurately by taking into account the number of adverse social factors affecting them, according to a new study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.
Providing medical school education free of debt not only relieves a significant financial burden, it may also help increase the diversity of the medical workforce, according to Weill Cornell Medicine leadership who studied the institution’s own experience.
A new test for measuring the reservoir of HIV hidden in the cells of people with HIV failed to detect this reservoir in a significant number of people with a subtype of HIV-1, according to a study from scientists at Weill Cornell Medicine, Simon Fraser University and the British Columbia Centre for Excellence in HIV/AIDS.
The risk of dying seven years after coronary artery bypass surgery was significantly lower in men receiving multiple bypass grafts rather than single grafts, but there was no apparent difference in mortality between these methods in women.
Researchers at Weill Cornell Medicine have gleaned new insights on the ways cells maintain the tips of their chromosomes, or telomeres. The findings help illuminate a wide range of phenomena, from cancer development to fungal evolution.
Patient mistrust of the healthcare system, which has come under new focus during the COVID-19 pandemic, is partly the result of an increasingly consumer-oriented healthcare system, according to a new commentary by a Weill Cornell Medicine investigator.
A gene therapy developed by Weill Cornell Medicine and NewYork-Presbyterian investigators helped slow progression of a rare and fatal genetic disorder in children called late infantile Batten disease, in a phase 1 clinical study.
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.
A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
The immunotherapy drug pembrolizumab, known by its brand name Keytruda, is a safe and effective option for patients with locally advanced and metastatic squamous cell esophageal cancer who have already received standard chemotherapy, according to a new study co-authored by a Weill Cornell Medicine and NewYork-Presbyterian investigator.
Weill Cornell Medicine has received a renewal of a prestigious grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to continue cutting-edge clinical research into treating and preventing infection with human immunodeficiency virus (HIV).
Space travel, illnesses like COVID-19, and climbing Mount Everest can trigger the body’s stress response systems in similar ways, according to new studies by Weill Cornell Medicine, space agencies and many other investigators.
Common symptoms of the genetic disorder neurofibromatosis type 1 (NF1), including skeletal fragility and the loss of bone mass, may be treatable with an existing anti-cancer drug, according to a study from researchers at Weill Cornell Medicine.
Molecular changes in cells called fibroblasts, which help provide support for tissues throughout the body, may explain why one type of colon cancer doesn’t respond to therapy.
Weill Cornell Medicine neuroscientist Dr. Li Gan is driving toward one of the most coveted medical breakthroughs: an effective treatment for Alzheimer’s disease.
Researchers at Weill Cornell Medicine have developed and used an advanced imaging technique to reveal the dynamics of two proteins required for many critical cellular functions, including cell division and neurotransmitter regulation. The findings could inform the development of future treatments for conditions in which these proteins are dysfunctional.
